Last reviewed · How we verify
NCT05308160
A Single Center, Randomized, Open Label, Parallel Group, Phase 3 Study to Evaluate the Efficacy of Dapagliflozin in Subjects With Nonalcoholic Fatty Liver Disease
Phase 3 trial testing Dapagliflozin 10Mg Tab in Fatty Liver in 75 participants. Status unknown.
30 June 2023
Quick facts
| Lead sponsor | National Taiwan University Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 75 |
| Start date | 28 June 2021 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 April 2024 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Dapagliflozin 10Mg Tab — full drug profile →
- Placebo
Conditions studied
- Fatty Liver — all drugs for Fatty Liver →
Sponsor
National Taiwan University Hospital
Who can join
Adults 20 to 74, any sex, with Fatty Liver. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a randomized, open label, two-arm, parallel-group, non-used comparator, single center trial to evaluate the efficacy of dapagliflozin in subjects with Nonalcoholic fatty liver disease. This is a principal investigator initiate study. This study is supported by Liver Disease Prevention \& Treatment Research Foundation. Dapagliflozin will be provided free of charge by AstraZeneca.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives.
Clayton-Chubb D, Kemp W, Majeed A, Lubel JS, et al · · 2023 · cited 26× · PMID 36771394 · DOI 10.3390/nu15030687 -
MetALD: Does it require a different therapeutic option?
Marek GW, Malhi H. · · 2024 · cited 21× · PMID 38820071 · DOI 10.1097/hep.0000000000000935 -
Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key.
Alonso-Peña M, Del Barrio M, Peleteiro-Vigil A, Jimenez-Gonzalez C, et al · · 2023 · cited 11× · PMID 37445895 · DOI 10.3390/ijms241310718 -
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development.
Khaznadar F, Khaznadar O, Petrovic A, Hefer M, et al · · 2024 · cited 10× · PMID 39057018 · DOI 10.3390/cimb46070376 -
Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy.
Amatya R, Lee D, Min KA, Shin MC. · · 2023 · cited 9× · PMID 37514148 · DOI 10.3390/pharmaceutics15071963 -
Hepatic Mechanisms of Myocardial Infarction: A New Perspective in Metabolic Dysfunction-Associated Fatty Liver Disease.
Cui J, Wang W, Xu Q, Zhu M, et al · · 2025 · PMID 40879000 · DOI 10.1161/jaha.124.040775
Verify or expand the search:
- PubMed search for NCT05308160
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dapagliflozin 10Mg Tab
Trials testing the same drug.
- NCT04930549 — Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC) · Phase 2 · completed
- NCT05254626 — Efficacy and Safety of Dapagliflozin in Patients with Non-alcoholic Steatohepatitis · Phase 2 · completed
- NCT05335629 — Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients · NA · completed
- NCT05343078 — Pharmacokinetics and Dialyzability of Dapagliflozin in Dialysis Patients · Phase 4 · completed
- NCT05268926 — TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension · Phase 2 · terminated
Other recruiting trials for Fatty Liver
Currently open trials in the same condition.
- NCT07242222 — Erdosteine in the Treatment of Nonalcoholic Fatty Liver Disease · Phase 1, PHASE2 · recruiting
- NCT07238985 — Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease · Phase 1, PHASE2 · recruiting
- NCT06661655 — Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients · NA · recruiting
- NCT06989723 — Pioglitazone and Empagliflozin for Fatty Liver Disease in Type 2 Diabetes · Phase 4 · recruiting
- NCT06203548 — Monitoring Changes in Hepatic Steatosis Using Continuous Controlled Attenuation Parameter · NA · recruiting
Other National Taiwan University Hospital trials
Trials by the same sponsor.
- NCT06936917 — Timing for Computed Tomography and Post-Resuscitation Care on Short-Term Outcomes in Out-of-Hospital Cardiac Arrest · not yet recruiting
- NCT05396222 — A Prospective Study of the Safety and Efficacy of 3D-printed Non-rigid Biomimetic Implant in Cervical and Thoracolumbar · NA · not yet recruiting
- NCT07532356 — Integrating Tumor Genomics and Urinary Exosomal Proteomics to Establish a Multi-Layer Biomarker Framework for Early Risk · not yet recruiting
- NCT07317310 — The NTU JO-SMART Study · NA · not yet recruiting
- NCT07382024 — Tirzepatide to Reduce rEcurrence And Burden After Ablation of Atrial Fibrillation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05308160 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Taiwan University Hospital
- Last refreshed: 1 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05308160.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing